Description
BMS-986523 is an investigational drug being studied by Bristol-Myers Squibb. It is currently in Phase 1 clinical trials for advanced solid cancers, including colorectal cancer. These early trials are designed to determine the safe dosage and how patients respond to the drug, both when given alone and in combination with other cancer treatments like cetuximab, gemcitabine, nab-paclitaxel, and pembrolizumab. The trials are looking at patients whose tumors have specific characteristics, such as KRAS amplification or PD-L1 expression. Because it is still in early development, the specific benefits and risks of BMS-986523 are still being evaluated.
Mechanism of Action
BMS-986523 is being investigated as a potential treatment for advanced solid cancers. The specific way it works (its mechanism of action) is still being studied in clinical trials. Researchers are working to understand how it affects cancer cells and whether it can help shrink tumors or slow their growth.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.